Copy
LISAvienna e-Newsletter 04/2014
View this email in your browser
 
Dear Readers, 

Develop your business idea and participate in BOB, the international business plan competition for life sciences run by aws on behalf of BMWFW. Deadline for submitting business ideas is September 15, 2014. Also remember the deadline for submitting R&D projects in response to the Life Sciences Call
at the Vienna Business Agency
which is September 17, 2014.
 
Life Science Circle: Increase your network at our second Life Science Circle this year! Join us on September 17, 2014 at the 6th Ã–GMBT Annual Meeting. Register here and check out photos and slides of our recent networking event at Tech Gate.
 
Business Treff: The ABF Pharmaceutical Services GmbH will open its new 1,300 m² GMP facility at Gastgebgasse on October 7, 2014. This is a marvelous occasion to get in contact with this specialist on labeling & packaging! Register now! 
 
Business Seminars: On October 13, 2014 there will be the opportunity to learn about smart preclinical casting for the best small molecules and biologics in drug development. The number of participants is limited, registration is open!. For October 28, 2014 a seminar on how to find the right sales partners for medical products is scheduled. Learn from your peers and register for this event.
 
We look forward to meeting you at one of the upcoming events in Vienna or at one of the international events we participate in the coming months.
 
However, for now, please enjoy reading some of the latest news below.
 

Kind regards!
LISAvienna
 
aws: Innovative Services Call
Up to 100,000 Euros grant money is
available for Start-ups focusing on innovative
technology-based services.
Applications for funding can either deal
with new services only or with
a combination of products
and services. In-house development
and novelty on the international scale are prerequisites for funding. Both funding for
the development stage and first steps
regarding market entry is available.
Deadline for the submission
of proposals is October 17, 2014.
 
Vienna Business Agency: Koop Pro Wien 2014
Vienna based companies are invited to submit applications for the funding of innovative cooperation projects with inter/national businesses with at least one of the partners being an SME. Up to 100,000 Euros are available per project. Both internal personnel and travel costs and external services are eligible for funding. Deadline for submission of proposals is September 16, 2014.
 
 
aws: License.IP 
Small and medium enterprises
are encouraged to profit
from intellectual property developed
by others, especially by public
research organizations. aws offers
support in the analysis of
technology needs, identification of
technological solutions, support in
licensing negotiations and funding for
the costs of in-licensing or purchasing of
patents and know-how. Up to 50 %
of licensing costs (max. 200,000 Euros)
can be covered by a non-repayable grant.
Vienna Business Agency: Innovations in Material Goods Production 
Innovative projects for the production
of material goods in Vienna are eligible
for funding at the Vienna Business Agency
for up to 100,000 Euros. Additional
prize money of 15,000 Euros will be
awarded to ”smart city projects“
allowing production processes that
conserve resources and energy,
involve recycling of resources,
space-saving production or the
production of energy-efficient products.
An extra bonus of 5,000 Euros
is available for start-ups.
Deadline is October 13, 2014.
aws: Equityfinder 
A new online platform has been developed
on behalf of BMWFW to bring start-ups
and SMEs in touch with private equity
investors such as venture capitalists,
business angels, crowd funding executives
and others. Potential private equity partners
can be easily screened via
the new “Equityfinder”.
Investors on the other hand can easily
check investment opportunities.
Vienna Business Agency: Internationalization 
SMEs, watch out: Have you already prepared
your strategy plan on how to enter
international key markets? The implementation
of you plans can be supported with up to 50,000 Euros in the Focus Internationalization scheme.
For single trade fairs and cross-border collaborations you are invited to apply
for the Internationalization Mission.
Up to 20,000 Euros funding
per company is available. Applications for
funding can be filed the whole year.
FUNDING Opportunities  in Vienna  

Deadlines to remember:
September 04: BRIDGE 1 Call (nanotechnology/converging technologies) closes at FFG >> 
September 15: Deadline for the submission of business ideas to BOB at aws >> 
September 15: Deadline „Focus Internationalization“ at Vienna Business Agency >> 
September 17: Life Sciences Call at the Vienna Business Agency closes >> 
September 23: PRIZE 2014, funding for prototypes by research organizations closes at aws >> 
October 17: Deadline for the new Innovative Services Call focusing on Start-ups at aws  >> 
NEWSFLASH    NEWSFLASH   NEWSFLASH   NEWSFLASH 
Visit www.LISAvienna.at for a comprehensive update
on the hottest news from the Life Science City Vienna!

Vetmeduni Vienna: Scientists uncover why major cow milk allergen is actually allergenic 

August 22, 2014 - Cow milk allergy occurs in children and in adults. Scientists at Messerli Research Institute at the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna found out that a certain protein in milk is able to initiate an allergy only when being devoid of iron. read more >> 
Recently, researchers at the Messerli Research Institute also developed the first cancer immunotherapy for dogs. read more >> 

MedUni Vienna: progress in the fight against harmful fungi

August 20, 2014 - A group of researchers at the Max F. Perutz Laboratories has created one of the three world's largest gene libraries for the Candida glabrata yeast. 28 new genes have been discovered that are partly responsible for the yeast's tolerance of common drugs. read more>>
Please also note the medical statistics expertise at MedUni Vienna as regards small population samples in rare diseases. read more>> 

BOKU Vienna: Origin of “mysterious drug” for Ebola 

August 8, 2014 - The Ebola epidemic lead to worldwide excitement about the origin of a novel plant-made drug produced by a US biotech company in green-houses in the States. The genetically modified tobacco production line for antibodies has been developed at BOKU in Vienna several years ago read more>>
Also not that the Center for World University Rankings ranks BOKU in among the top 3.3 % of universities worldwide read more>> 

AFFiRiS: presented first clinical data of therapeutic Parkinson's disease vaccine 

July 31, 2014 - In this phase I study, two different doses of PD01A were safe and well tolerated. The vaccine candidate is the first therapy against the protein alpha-synuclein to enter clinical testing. The study has been supported by The Michael J. Fox Foundation. read more>> 

Baxter: Baxter announced divestiture of commercial vaccines business to Pfizer 

July 30, 2014 - Baxter International Inc. announced to sell its two commercially marketed vaccines helping to protect against group C meningococcal meningitis and tick-borne encephalitis and related production facilities to Pfizer Inc. for a total cash consideration of $635 million. read more>>

Valneva  announced new antibody discovery collaboration with a leading global animal health company 

July 28, 2014 - Valneva SE (“Valneva”) announced the signing of a research collaboration and license agreement with a leading global animal health care company to discover antibodies from animal B-lymphocytes using Valneva’s proprietary VIVA|Screen® technology. read more>>

Miracor Medical Systems launched next-generation product to reduce severe heart attack impairment in Europe

July 22, 2014 - Miracor Medical Systems announced today the successful launch of its next-generation PICSO® Impulse System for the treatment of myocardial infarction. The new System, consisting of the Impulse Console and Impulse Balloon Catheters, is CE-marked and has already been used to treat patients in the U.K., Ireland, and Hungary. read more>>
 

TAmiRNA:  miRNAs in the plasma of HIV elite controllers reduce HIV infection in vitro

July 16, 2014 - Scientists from Argentina and Vienna have recently shown that miRNAs are differentially present in plasma samples from healthy, chronically HIV-infected and HIV-resistant individuals, and that these miRNAs can suppress HIV replication in vitro. read more >>

 
APEPTICO 
announced break-through results in scientific understanding of alveolar liquid clearance regulation

July 16, 2014 - A co-founder of the privately held biotechnology company developing peptide drugs has discovered important new results regarding the scientific understanding of alveolar liquid clearance regulation by the apically expressed pulmonary epithelial sodium channel (ENaC). read more>>

University of Applied Sciences Technikum: new steering technologies for disabled people and the elderly

July 14, 2014 – UAS Technikum Wien increases its research activities in assistive technologies. For example, extensive know-how on individualized mouth controlled mouse systems, eye tracking and various smart home technologies is available. read more>>

Apeiron to start first clinical trial in Japan with its Neuroblastoma therapy APN311 

July 7, 2014 – The phase I clinical trial will be conducted by Nagoya University Hospital and is part of a long-term collaboration to make this therapy available to patients suffering from this severe type of children’s cancer. In Japan, it won a grant by the Japanese government. read more>>

MedUni Wien: Novartis in Austria drives innovations for patients 

July 7, 2014 – A new publication on value creation reveals the key role of Novartis for Austria's research and business location. About one fourth of all employees in pharmaceuticals work with Novartis and generate about one third of the total annual added value.
Also note: This year's Novartis Award in Pathology has been awarded to a researcher in Austria: Lukas Kenner read more>>

TU Vienna:  sweet sweet straw

June 26, 2014 - The calorie free sweetener erythritol is widely used in Asia; it is also gaining popularity in Europe and America. At the Vienna University of Technology, a new cheap method has been developed to produce erythritol from straw with the help of mold fungi. read more>>

 TÃœV Austria:  new publication on legislation regarding medical products in Austria 

June 24, 2014 - Across more than 600 pages the second edition of this book presents the most important laws and regulations concerning medical products in Austria. read more>>
 

IMBA  director Josef Penninger receives Wittgenstein Award 2014 

June 17, 2014 - The geneticist has been honored for his scientific achievements in the fields of biomedicine and disease pattern research. At 1.5 Million Euros, the Wittgenstein Award is the most prestigious and highly endowed prize awarded to scientists in Austria. read more>>
This list is not exhaustive. For more news  please visit our website www.LISAvienna.at.
Your news placed here: Vienna-based organizations are invited to e-mail news and press releases to news@LISAvienna.at to contribute to LISAvienna's digital and print media.
Upcoming EVENTS in Vienna  
  • Crossing Frontiers in Life Sciences 
    September 11-12, 2014
    University of Vienna, Kleiner Festsaal, Universitätsring 1, 1010 Vienna
    This year, Max F. Perutz, the Austrian Nobel Prize winner, would have turned 100. On this occasion, the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna have organized the symposium "Crossing Frontiers in Life Sciences". 14 highly renowned scientists and 10 MFPL researchers will talk about structural biology, cell signaling, bioinformatics, RNA biology, and chromosome dynamics.
    Info & registration details 
    Info

  • 50th Annual Meeting of the European Association for the Study of Diabetes (EASD)
    September 15-19, 2014
    Messe Wien Exhibition & Congress Center, Messeplatz 1, 1020 Vienna
    The mission of EASD is to promote excellence in diabetes care through research and education. EASD runs the largest scientific and clinical diabetes meeting in the world which serves to advance the current understanding of diabetes, encourage collaboration and to disseminate knowledge. 18,000 delegates from over 100 countries will gather in Vienna in September. Even more are expected to participate online via EASD's
    Virtual Meeting Platform.
    Info & registration details 

  • Innovation Talk: User Experience as USP in Health Care
    September 23 2014
    Expat Center, Schmerlingplatz 3, 1010 Vienna
    The Vienna Business Agency offers up-to-date insights regarding user experience as a special asset in health care. Learn more about this hot topic in 10 staccato presentations, participate in workshops on diversity & UX, UX & product placement as well as UX & compliance and let your network grow.
    Info & registration details 

  • Methodology of Clinical Trials in Oncology
    November 27-29, 2014
    Hotel & Palais Strudlhof, Sigmund Freud room, Strudlhofgasse 10, 1090 Vienna
    For the 17th time, the ”Deutschsprachig-Europäische Schule für Onokologie, DESO“ initiated a high level seminar covering all major aspects regarding clinical trials in cancer. The program includes regulatory aspects, data management, databases in oncology, planning and carrying out clinical studies (phase I-III), special aspects linked to multi-modal therapies as well as general limits and pitfalls of clinical trials in oncology.
    Info & registration details
Copyright © LISAvienna 2014, All rights reserved.
Photo Intro © LISAvienna - Marcus Schieder


Our mailing address is: office@LISAvienna.at

unsubscribe from this list    update subscription preferences 

LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economics and the city of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.